M A Gamaleldin1, O M Ghallab2, E A Nadwan2, R A Abo Elwafa3. 1. Clinical Pathology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt. marwa.gamal@alexmed.edu.eg. 2. Internal Medicine Department (Hematology Unit), Faculty of Medicine, University of Alexandria, Alexandria, Egypt. 3. Clinical Pathology Department, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
Abstract
PURPOSE: The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligand, programmed cell death ligand-1 (PD-L1), is expressed on the surface of dendritic cells or macrophages. The PD-1/PD-L1 interaction ensures prevention of autoimmunity by activating the immune system only when needed. In cancers, PD-L1 expressed on the tumour cells binds to PD-1 receptors on the activated T cells, leading to inhibition of the cytotoxic T cells and immunosuppression. PD-1/PD-L1 pathway is upregulated in EBV infection that is known to worsen the CLL prognosis. Therefore, we aimed to study the association between PD-1 and PD-L1 expressions, EBV status and the CLL prognosis. METHODS AND PATIENTS: The study was conducted on 80 newly diagnosed CLL patients and 80 controls. We analyzed PD-1 and PD-L1 expressions and EBV-DNA load by real-time PCR. The cytogenetic abnormalities and expression of ZAP70 and CD38 were detected by FISH and Flow cytometry, respectively. RESULTS: PD-1/PD-L1 expressions were significantly upregulated in CLL patients compared to controls. In addition, their mRNA levels were significantly higher in EBV( +) versus EBV( -) patients. High expression of PD-1/PD-L1 was associated with poor prognostic markers (RAI stages of CLL, del 17p13, ZAP70, and CD38 expression), failure of complete remission, shorter progression-free survival, and overall survival. CONCLUSION: High expression of PD-1 and PD-L1, together with high EBD-DNA load were linked to worse prognosis in CLL. In addition, PD-1 and PD-L1 might represent suitable therapeutic targets for patients suffering from aggressive CLL.
PURPOSE: The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligand, programmed cell death ligand-1 (PD-L1), is expressed on the surface of dendritic cells or macrophages. The PD-1/PD-L1 interaction ensures prevention of autoimmunity by activating the immune system only when needed. In cancers, PD-L1 expressed on the tumour cells binds to PD-1 receptors on the activated T cells, leading to inhibition of the cytotoxic T cells and immunosuppression. PD-1/PD-L1 pathway is upregulated in EBV infection that is known to worsen the CLL prognosis. Therefore, we aimed to study the association between PD-1 and PD-L1 expressions, EBV status and the CLL prognosis. METHODS AND PATIENTS: The study was conducted on 80 newly diagnosed CLL patients and 80 controls. We analyzed PD-1 and PD-L1 expressions and EBV-DNA load by real-time PCR. The cytogenetic abnormalities and expression of ZAP70 and CD38 were detected by FISH and Flow cytometry, respectively. RESULTS: PD-1/PD-L1 expressions were significantly upregulated in CLL patients compared to controls. In addition, their mRNA levels were significantly higher in EBV( +) versus EBV( -) patients. High expression of PD-1/PD-L1 was associated with poor prognostic markers (RAI stages of CLL, del 17p13, ZAP70, and CD38 expression), failure of complete remission, shorter progression-free survival, and overall survival. CONCLUSION: High expression of PD-1 and PD-L1, together with high EBD-DNA load were linked to worse prognosis in CLL. In addition, PD-1 and PD-L1 might represent suitable therapeutic targets for patients suffering from aggressive CLL.
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps Journal: Blood Date: 2018-03-14 Impact factor: 22.113
Authors: Małgorzata Rusak; Andrzej Eljaszewicz; Łukasz Bołkun; Ewa Łuksza; Izabela Łapuć; Jarosław Piszcz; Paulina Singh; Milena Dąbrowska; Anna Bodzenta-Łukaszyk; Janusz Kłoczko; Marcin Moniuszko Journal: Pol Arch Med Wewn Date: 2015-07-03
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Stephanie A Smoley; Daniel L Van Dyke; Neil E Kay; Nyla A Heerema; Marie L Dell' Aquila; Paola Dal Cin; Prasad Koduru; Ayala Aviram; Laura Rassenti; John C Byrd; Kanti R Rai; Jennifer R Brown; Andrew W Greaves; Jeanette Eckel-Passow; Donna Neuberg; Thomas J Kipps; Gordon W Dewald Journal: Cancer Genet Cytogenet Date: 2010-12
Authors: Alessandra Ferrajoli; Cristina Ivan; Maria Ciccone; Masayoshi Shimizu; Yoshiaki Kita; Masahisha Ohtsuka; Lucilla D'Abundo; Jun Qiang; Susan Lerner; Nazila Nouraee; Kari G Rabe; Laura Z Rassenti; Katrien Van Roosbroeck; John T Manning; Yuan Yuan; Xinna Zhang; Tait D Shanafelt; William G Wierda; Silvia Sabbioni; Jeffrey J Tarrand; Zeev Estrov; Milan Radovich; Han Liang; Massimo Negrini; Thomas J Kipps; Neil E Kay; Michael Keating; George A Calin Journal: EBioMedicine Date: 2015-04-29 Impact factor: 8.143